Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18989169 | Compositions and Methods for Analyte Detection | December 2024 | November 2025 | Abandon | 11 | 1 | 1 | Yes | No |
| 18622344 | NEXT-GENERATION SEQUENCING FOR PROTEIN MEASUREMENT | March 2024 | August 2025 | Allow | 17 | 1 | 0 | No | No |
| 18615301 | Compositions and Methods for Analyzing Modified Nucleotides | March 2024 | December 2025 | Allow | 21 | 1 | 0 | No | No |
| 18433345 | COMPOSITIONS AND METHODS FOR ANALYZING CELL-FREE DNA IN METHYLATION PARTITIONING ASSAYS | February 2024 | February 2026 | Allow | 24 | 3 | 0 | Yes | No |
| 18419411 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | January 2024 | October 2024 | Allow | 8 | 2 | 0 | Yes | No |
| 18530860 | METHODS OF DETECTING A LEAK FROM A SUBARRAY OF A MICROARRAY CHIP, KITS OF COMPONENTS THAT FACILITATE LEAK DETECTION, AND MICROARRAY CHIPS CONFIGURED FOR LEAK DETECTION | December 2023 | September 2024 | Allow | 9 | 2 | 1 | Yes | No |
| 18522844 | Transcriptome In Vivo Analysis (TIVA) and Transcriptome In Situ Analysis (TISA) | November 2023 | February 2026 | Allow | 27 | 2 | 1 | No | No |
| 18379480 | LYSIS BUFFERS FOR EXTRACTING NUCLEIC ACIDS | October 2023 | October 2025 | Abandon | 24 | 1 | 1 | Yes | No |
| 18459068 | Compositions and Methods for Analyte Detection | August 2023 | March 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18454312 | Method to Use Gene Expression to Determine Likelihood of Clinical Outcome of Renal Cancer | August 2023 | May 2025 | Allow | 21 | 1 | 1 | No | No |
| 18452778 | CIRCULATING SERUM MICRORNA BIOMARKERS AND METHODS FOR PARKINSON'S DISEASE PROGNOSIS | August 2023 | May 2025 | Allow | 21 | 1 | 0 | No | No |
| 18446093 | SYSTEM, METHOD, COMPUTER-ACCESSIBLE MEDIUM AND APPARATUS FOR DNA MAPPING | August 2023 | July 2025 | Allow | 23 | 1 | 0 | No | No |
| 18229064 | LARGE-SCALE EPIGENOMIC REPROGRAMMING LINKS ANABOLIC GLUCOSE METABOLISM TO DISTANT METASTASIS DURING THE EVOLUTION OF PANCREATIC CANCER PROGRESSION | August 2023 | October 2025 | Abandon | 26 | 1 | 0 | No | No |
| 18208770 | NUCLEIC ACID SEQUENCING ADAPTERS AND USES THEREOF | June 2023 | September 2025 | Allow | 27 | 2 | 0 | No | No |
| 18327614 | DETECTING OVARIAN CANCER | June 2023 | June 2025 | Allow | 25 | 2 | 1 | No | No |
| 18112696 | NEEDLE-BASED DEVICES AND METHODS FOR IN VIVO DIAGNOSTICS OF DISEASE CONDITIONS | February 2023 | January 2025 | Abandon | 23 | 0 | 1 | No | No |
| 18163128 | METHODS AND SYSTEMS FOR HIGH-DEPTH SEQUENCING OF METHYLATED NUCLEIC ACID | February 2023 | June 2025 | Allow | 29 | 5 | 1 | Yes | No |
| 18156434 | REPEAT RNA AS BIOMARKERS OF TUMOR IMMUNE RESPONSE | January 2023 | July 2025 | Abandon | 30 | 1 | 0 | No | No |
| 18097989 | METHODS AND SYSTEMS FOR SAMPLE PREPARATION AND ANALYSIS | January 2023 | July 2025 | Allow | 30 | 2 | 0 | Yes | No |
| 18056951 | METHODS FOR CHARACTERIZING CELL-FREE NUCLEIC ACID FRAGMENTS | November 2022 | March 2026 | Allow | 40 | 3 | 0 | Yes | No |
| 17962752 | Method and Device for Encapsulating Cell in Liquid Droplet for Single-Cell Analysis | October 2022 | December 2024 | Allow | 26 | 1 | 0 | Yes | No |
| 17936745 | NANO46 GENES AND METHODS TO PREDICT BREAST CANCER OUTCOME | September 2022 | February 2026 | Abandon | 40 | 3 | 0 | No | No |
| 17955426 | POLYMORPHISM DETECTION WITH INCREASED ACCURACY | September 2022 | December 2024 | Abandon | 27 | 1 | 0 | No | No |
| 17930901 | MARKERS SPECIFIC FOR PLURIPOTENT STEM CELLS, AND METHODS OF USING THE SAME | September 2022 | October 2025 | Allow | 38 | 4 | 1 | Yes | No |
| 17820925 | Clear Cell Renal Cell Carcinoma Biomarkers | August 2022 | August 2024 | Allow | 24 | 1 | 0 | Yes | No |
| 17888361 | PROBES COMPRISING A SPLIT BARCODE REGION AND METHODS OF USE | August 2022 | July 2025 | Allow | 35 | 2 | 0 | No | No |
| 17929033 | TARGETED, LONG-READ NUCLEIC ACID SEQUENCING FOR THE DETERMINATION OF CYTOSINE MODIFICATIONS | August 2022 | December 2025 | Allow | 40 | 1 | 0 | Yes | No |
| 17813965 | ASSAY METHODS | July 2022 | May 2025 | Allow | 34 | 2 | 1 | No | No |
| 17867430 | SEQUENCE ASSEMBLY | July 2022 | September 2025 | Allow | 38 | 1 | 0 | No | No |
| 17849917 | METHODS, COMPOSITIONS, AND KITS FOR ASSAY SIGNAL AMPLIFICATION | June 2022 | March 2026 | Allow | 44 | 1 | 1 | No | No |
| 17787866 | MULTIPLEX DROP-OFF DIGITAL POLYMERASE CHAIN REACTION METHODS | June 2022 | March 2026 | Allow | 45 | 1 | 1 | No | No |
| 17782916 | METHODS AND COMPOSITIONS FOR TREATING CANCERS HAVING F-BOX AND WD-REPEAT PROTEIN 7 (FBXW7) ALTERATIONS AND/OR CYCLIN L1 (CCNL1) GAIN OR AMPLIFICATION | June 2022 | January 2026 | Abandon | 44 | 0 | 1 | No | No |
| 17781083 | SYSTEM AND METHOD FOR IDENTIFYING ANALYTES IN ASSAY USING NORMALIZED TM VALUES | May 2022 | May 2025 | Allow | 35 | 2 | 1 | Yes | No |
| 17780798 | METHODS OF TREATING CANCER | May 2022 | November 2025 | Allow | 42 | 1 | 0 | No | No |
| 17740212 | HYDROXYMETHYLATION ANALYSIS OF CELL-FREE NUCLEIC ACID SAMPLES FOR ASSIGNING TISSUE OF ORIGIN, AND RELATED METHODS OF USE | May 2022 | November 2025 | Allow | 42 | 3 | 0 | No | No |
| 17711769 | ASSAY SYSTEMS FOR GENETIC ANALYSIS | April 2022 | March 2025 | Allow | 35 | 2 | 0 | Yes | Yes |
| 17694443 | METHODS FOR IDENTIFYING CARRIER STATUS AND ASSESSING RISK FOR SPINAL MUSCULAR ATROPHY | March 2022 | March 2026 | Abandon | 48 | 4 | 0 | No | No |
| 17585814 | METHODS AND KITS FOR DETECTION OF METHYLATION STATUS | January 2022 | June 2025 | Abandon | 41 | 5 | 0 | Yes | No |
| 17627166 | PRIMERS FOR ISOTHERMAL AMPLIFICATION | January 2022 | July 2025 | Abandon | 42 | 0 | 1 | No | No |
| 17625500 | BISULFITE-FREE, WHOLE GENOME METHYLATION ANALYSIS | January 2022 | May 2025 | Allow | 40 | 2 | 0 | No | No |
| 17561562 | DETECTION OF TARGET NUCLEIC ACIDS USING HYBRIDIZATION | December 2021 | August 2024 | Allow | 32 | 1 | 0 | No | No |
| 17553182 | METHOD FOR RELATIVE QUANTIFICATION OF NUCLEIC ACID SEQUENCE, EXPRESSION, OR COPY CHANGES, USING COMBINED NUCLEASE, LIGATION, AND POLYMERASE REACTIONS | December 2021 | August 2024 | Allow | 32 | 1 | 1 | No | No |
| 17543806 | METHOD FOR GENERATING DOUBLE STRANDED DNA LIBRARIES AND SEQUENCING METHODS FOR THE IDENTIFICATION OF METHYLATED CYTOSINES | December 2021 | January 2026 | Abandon | 50 | 3 | 0 | No | Yes |
| 17616211 | METHOD FOR DETECTING METHYLATION OF SDC2 GENE | December 2021 | July 2025 | Allow | 44 | 1 | 1 | Yes | No |
| 17536306 | GENETIC MARKERS FOR ENHANCING EFFICACY OF ANTIPSYCHOTIC TREATMENT WITH ILOPERIDONE | November 2021 | August 2024 | Allow | 32 | 2 | 0 | No | No |
| 17613825 | COMPOSITIONS AND METHODS FOR PRESERVING DNA METHYLATION | November 2021 | October 2025 | Allow | 47 | 7 | 0 | Yes | No |
| 17521205 | COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF A GASTROENTEROPANCREATIC NEUROENDOCRINE NEOPLASM | November 2021 | November 2024 | Allow | 36 | 1 | 1 | No | No |
| 17487804 | METHODS OF SEQUENCING NUCLEIC ACID MOLECULES | September 2021 | May 2025 | Abandon | 43 | 7 | 0 | Yes | No |
| 17448958 | METHOD FOR HIGHLY SENSITIVE DNA METHYLATION ANALYSIS | September 2021 | August 2024 | Allow | 35 | 2 | 0 | No | No |
| 17441207 | SERIAL BIOMARKER MEASUREMENT USING A COMPARATOR APPROACH | September 2021 | April 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17404303 | BACTERIOPHAGE TREATMENT AND REDUCTION IN INFLAMMATORY RESPONSE | August 2021 | July 2025 | Allow | 47 | 1 | 1 | No | No |
| 17428219 | DARC EXPRESSION AS PROGNOSTICATOR OF IMMUNOTHERAPY OUTCOMES | August 2021 | April 2025 | Allow | 45 | 2 | 1 | Yes | No |
| 17388537 | HIGH THROUGHPUT ANALYSIS OF FIXED CELLS | July 2021 | January 2026 | Allow | 54 | 4 | 1 | Yes | No |
| 17292748 | GENE SIGNATURES FOR THE PREDICTION OF PROSTATE CANCER RECURRENCE | May 2021 | November 2024 | Allow | 42 | 1 | 1 | Yes | No |
| 17285629 | NUTLIN-3A FOR USE IN TREATING A MYCOBACTERIUM TUBERCULOSIS INFECTION | April 2021 | December 2025 | Abandon | 56 | 3 | 1 | Yes | No |
| 17282694 | SIMULTANEOUS, SEQUENCING-BASED ANALYSIS OF PROTEINS, NUCLEOSOMES, AND CELL-FREE NUCLEIC ACIDS FROM A SINGLE BIOLOGICAL SAMPLE | April 2021 | September 2025 | Allow | 54 | 1 | 1 | No | No |
| 17198932 | GENOTYPING BY POLYMERASE BINDING | March 2021 | October 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17273014 | RECURRENCE GENE SIGNATURE ACROSS MULTIPLE CANCER TYPES | March 2021 | June 2025 | Abandon | 51 | 2 | 1 | No | No |
| 17173770 | METHODS AND SYSTEMS FOR HIGH-DEPTH SEQUENCING OF METHYLATED NUCLEIC ACID | February 2021 | September 2025 | Allow | 55 | 3 | 1 | Yes | No |
| 17131287 | PANCREATIC DUCTAL ADENOCARCINOMA EVALUATION USING CELL-FREE DNA HYDROXYMETHYLATION PROFILE | December 2020 | January 2025 | Abandon | 48 | 1 | 1 | No | No |
| 17255316 | POLYNUCLEOTIDE DUPLEX PROBE MOLECULE | December 2020 | July 2025 | Abandon | 54 | 3 | 1 | No | No |
| 17109493 | PROBE, PROBE SET, AND METHOD FOR IDENTIFYING DESIRED DNA SEQUENCE IN SOLUTION | December 2020 | May 2025 | Allow | 53 | 5 | 1 | Yes | No |
| 17032023 | METHODS OF SEQUENCING NUCLEIC ACID MOLECULES | September 2020 | August 2025 | Abandon | 59 | 2 | 0 | Yes | Yes |
| 17025822 | METHODS AND SYSTEMS FOR T CELL RECEPTOR ANALYSIS | September 2020 | December 2024 | Abandon | 51 | 4 | 1 | Yes | No |
| 16969892 | METHODS FOR ISOLATING NUCLEIC ACIDS WITH SIZE SELECTION | August 2020 | July 2025 | Allow | 59 | 3 | 1 | Yes | No |
| 16966354 | SAMPLE PREP FOR DNA LINKAGE RECOVERY | July 2020 | May 2025 | Allow | 57 | 5 | 0 | Yes | No |
| 15733113 | CHEMICAL PROBE-DEPENDENT EVALUATION OF PROTEIN ACTIVITY AND USES THEREOF | May 2020 | December 2024 | Allow | 55 | 2 | 1 | No | No |
| 16763553 | BIOMARKER PROXY TESTS AND METHODS FOR STANDARD BLOOD CHEMISTRY TESTS | May 2020 | March 2025 | Abandon | 58 | 6 | 1 | Yes | No |
| 16470586 | Deconvolution and Detection of Rare DNA in Plasma | June 2019 | August 2025 | Allow | 60 | 9 | 0 | Yes | No |
| 16322462 | SEQUENTIAL PROBING OF MOLECULAR TARGETS BASED ON PSEUDO-COLOR BARCODES WITH EMBEDDED ERROR CORRECTION MECHANISM | January 2019 | May 2025 | Allow | 60 | 4 | 1 | Yes | No |
| 16194612 | METHOD AND KIT FOR TARGET MOLECULE DETECTION | November 2018 | January 2025 | Abandon | 60 | 6 | 0 | Yes | Yes |
| 16005228 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER | June 2018 | November 2019 | Allow | 17 | 1 | 0 | No | No |
| 15775015 | METHODS OF DETECTING 5-HYDROXYMETHYLCYTOSINE AND DIAGNOSING OF CANCER | May 2018 | February 2025 | Abandon | 60 | 7 | 1 | Yes | Yes |
| 15967395 | MICROARRAYS | April 2018 | April 2025 | Abandon | 60 | 6 | 1 | Yes | Yes |
| 15741344 | DROPLET SEQUENCING DEVICE | January 2018 | October 2019 | Allow | 21 | 1 | 1 | No | No |
| 15531397 | MULTIPLEX BEAD ARRAY ASSAY | May 2017 | August 2019 | Allow | 27 | 1 | 1 | Yes | No |
| 15515185 | USE OF HLA GENETIC STATUS TO ASSESS OR SELECT TREATMENT OF CELIAC DISEASE | March 2017 | March 2019 | Allow | 24 | 1 | 1 | No | No |
| 15443499 | MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PROSTATE CANCER | February 2017 | January 2019 | Allow | 23 | 1 | 1 | Yes | No |
| 15437147 | METHODS FOR IDENTIFYING SUBJECTS WITH A GENETIC RISK FOR DEVELOPING IGA NEPHROPATHY | February 2017 | March 2019 | Allow | 25 | 1 | 1 | Yes | No |
| 15315482 | NUCLEOTIDE POLYMORPHISM DETECTION METHOD | December 2016 | December 2018 | Allow | 24 | 1 | 0 | Yes | No |
| 15273205 | METHODS FOR TREATING DIFFUSE LARGE B-CELL LYMPHOMA AND THE USE OF BIOMARKERS AS A PREDICTOR OF RESPONSIVENESS TO DRUGS | September 2016 | February 2020 | Allow | 41 | 3 | 1 | Yes | No |
| 15272283 | CANCER TREATMENT WITH C-MET ANTAGONISTS AND CORRELATION OF THE LATTER WITH HGF EXPRESSION | September 2016 | October 2018 | Allow | 25 | 1 | 1 | No | No |
| 15221154 | METHOD AND COMPOSITIONS FOR DETECTING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT FORMS IN CANCER CELLS | July 2016 | November 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 15032325 | NUCLEIC ACIDS AND METHODS FOR DETECTING PATHOGENS AND BENEFICIAL MICROORGANISMS | April 2016 | June 2019 | Allow | 49 | 4 | 0 | Yes | No |
| 14938240 | HYBRIDIZATION PROBES AND METHODS | November 2015 | March 2018 | Allow | 28 | 2 | 1 | Yes | No |
| 14890424 | DNA Methylation Biomarkers for Bladder Cancer | November 2015 | October 2019 | Allow | 47 | 3 | 1 | Yes | No |
| 14788195 | MATERIALS AND METHODS FOR ASSESSING PROGRESSION OF PROSTATE CANCER | June 2015 | January 2018 | Allow | 30 | 3 | 1 | Yes | No |
| 14294011 | DETECTION OF NUCLEIC ACIDS USING UNMODIFIED GOLD NANOPARTICLES | June 2014 | September 2017 | Allow | 40 | 2 | 0 | Yes | Yes |
| 13981601 | Colon Cancer Gene Expression Signatures and Methods of Use | October 2013 | September 2018 | Allow | 60 | 4 | 1 | Yes | Yes |
| 13823730 | CAPTURE BASED NUCLEIC ACID DETECTION | May 2013 | January 2016 | Allow | 34 | 1 | 1 | No | No |
| 13728912 | METHOD AND COMPOSITIONS FOR DETECTING EPIDERMAL GROWTH FACTOR RECEPTOR VARIANT FORMS IN CANCER CELLS | December 2012 | March 2016 | Allow | 39 | 2 | 1 | Yes | No |
| 13724527 | MICROORGANISM NUCLEIC ACID PURIFICATION FROM HOST SAMPLES | December 2012 | August 2017 | Allow | 56 | 6 | 0 | No | No |
| 13721081 | MATERIALS AND METHODS FOR DIAGNOSIS, PROGNOSIS AND ASSESSMENT OF THERAPEUTIC/PROPHYLACTIC TREATMENT OF PROSTATE CANCER | December 2012 | November 2016 | Allow | 47 | 3 | 1 | Yes | No |
| 13502518 | METHODS AND SYSTEMS FOR PHARMACOGENOMIC TREATMENT OF CARDIOVASCULAR CONDITIONS | September 2012 | June 2016 | Allow | 50 | 4 | 2 | Yes | No |
| 12864641 | METHOD AND DEVICE FOR THE AUTOMATED PROCESSING OF A SAMPLE | December 2011 | November 2014 | Allow | 52 | 3 | 0 | Yes | No |
| 13259350 | Bioagent Detection Systems, Devices, And Methods | November 2011 | June 2016 | Allow | 56 | 5 | 0 | Yes | No |
| 13187190 | BIOLAYER INTERFEROMETRY MEASUREMENT OF BIOLOGICAL TARGETS | July 2011 | July 2013 | Allow | 23 | 1 | 1 | Yes | No |
| 13173247 | ULTRA HIGH-THROUGHPUT OPTI-NANOPORE DNA READOUT PLATFORM | June 2011 | January 2014 | Allow | 30 | 3 | 0 | Yes | No |
| 13152260 | Methods and Systems for Sequential Determination of Genetic Mutations and/or Varients | June 2011 | July 2017 | Allow | 60 | 6 | 0 | No | No |
| 13062247 | METHOD FOR DETECTION OF CANCER BASED ON SPATIAL GENOME ORGANIZATION | March 2011 | November 2016 | Allow | 60 | 5 | 1 | Yes | Yes |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner DAUNER, JOSEPH G.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 16.7% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner DAUNER, JOSEPH G works in Art Unit 1682 and has examined 73 patent applications in our dataset. With an allowance rate of 80.8%, this examiner has an above-average tendency to allow applications. Applications typically reach final disposition in approximately 47 months.
Examiner DAUNER, JOSEPH G's allowance rate of 80.8% places them in the 51% percentile among all USPTO examiners. This examiner has an above-average tendency to allow applications.
On average, applications examined by DAUNER, JOSEPH G receive 3.25 office actions before reaching final disposition. This places the examiner in the 91% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by DAUNER, JOSEPH G is 47 months. This places the examiner in the 9% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +11.6% benefit to allowance rate for applications examined by DAUNER, JOSEPH G. This interview benefit is in the 46% percentile among all examiners. Recommendation: Interviews provide a below-average benefit with this examiner.
When applicants file an RCE with this examiner, 19.6% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 27.9% of cases where such amendments are filed. This entry rate is in the 39% percentile among all examiners. Strategic Recommendation: This examiner shows below-average receptiveness to after-final amendments. You may need to file an RCE or appeal rather than relying on after-final amendment entry.
When applicants request a pre-appeal conference (PAC) with this examiner, 100.0% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 70% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 3% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.0% of allowed cases (in the 3% percentile). This examiner rarely issues Quayle actions compared to other examiners. Allowances typically come directly without a separate action for formal matters.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.